TW202406532A - 抗羰基化組成物及藉由使用包括聚離胺酸之組成物來保護角蛋白材料免於羰基化刺激之方法 - Google Patents
抗羰基化組成物及藉由使用包括聚離胺酸之組成物來保護角蛋白材料免於羰基化刺激之方法 Download PDFInfo
- Publication number
- TW202406532A TW202406532A TW112128308A TW112128308A TW202406532A TW 202406532 A TW202406532 A TW 202406532A TW 112128308 A TW112128308 A TW 112128308A TW 112128308 A TW112128308 A TW 112128308A TW 202406532 A TW202406532 A TW 202406532A
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- carbonylation
- polylysine
- skin
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000005810 carbonylation reaction Methods 0.000 title claims abstract description 66
- 229920000656 polylysine Polymers 0.000 title claims abstract description 61
- 230000006315 carbonylation Effects 0.000 title claims abstract description 30
- 102000011782 Keratins Human genes 0.000 title claims abstract description 17
- 108010076876 Keratins Proteins 0.000 title claims abstract description 17
- 239000000463 material Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 239000002537 cosmetic Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 63
- 108010039918 Polylysine Proteins 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 235000018102 proteins Nutrition 0.000 claims description 38
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 23
- 239000004472 Lysine Substances 0.000 claims description 11
- -1 glycerin) Chemical class 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 235000019766 L-Lysine Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 244000144927 Aloe barbadensis Species 0.000 claims description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 229930003537 Vitamin B3 Natural products 0.000 claims description 2
- 229930003571 Vitamin B5 Natural products 0.000 claims description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019160 vitamin B3 Nutrition 0.000 claims description 2
- 239000011708 vitamin B3 Substances 0.000 claims description 2
- 235000009492 vitamin B5 Nutrition 0.000 claims description 2
- 239000011675 vitamin B5 Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 35
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 108091006003 carbonylated proteins Proteins 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007854 depigmenting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
- GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 description 2
- YDZIJQXINJLRLL-UHFFFAOYSA-N 2-hydroxydodecanoic acid Chemical compound CCCCCCCCCCC(O)C(O)=O YDZIJQXINJLRLL-UHFFFAOYSA-N 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- KGULFLCOPRYBEV-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCO KGULFLCOPRYBEV-KTKRTIGZSA-N 0.000 description 1
- PWQNOLAKMCLNJI-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethyl dihydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOP(O)(O)=O PWQNOLAKMCLNJI-KTKRTIGZSA-N 0.000 description 1
- IKRKINIKITZMKG-UHFFFAOYSA-N 2-hydroxy-5-octylbenzoic acid Chemical compound CCCCCCCCC1=CC=C(O)C(C(O)=O)=C1 IKRKINIKITZMKG-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical class 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 229940094978 bis-peg-18 methyl ether dimethyl silane Drugs 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 229940031722 methyl gluceth-20 Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- WPBWJEYRHXACLR-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O.OC(=O)CCCCCCCC(O)=O WPBWJEYRHXACLR-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940075643 oleth-3 Drugs 0.000 description 1
- 229940093440 oleth-3-phosphate Drugs 0.000 description 1
- 229940093446 oleth-5 Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申請案係關於一種減少及/或抑制蛋白質羰基化之組成物,該組成物包括聚離胺酸。本申請案進一步關於一種藉由使用包括聚離胺酸之組成物來保護皮膚免於羰基化刺激之方法,且關於一種藉由施加包括聚離胺酸之該減少及/或抑制蛋白質羰基化之組成物來護理角蛋白材料之非治療美容方法,尤其是護理皮膚。
Description
本申請案係關於包括(多種)聚離胺酸之抗羰基化組成物,且進一步係關於減少及/或抑制蛋白質羰基化之方法,特別是藉由使用包括(多種)聚離胺酸之組成物來保護組織(例如,角蛋白材料,尤其是(多種)角蛋白纖維,諸如皮膚等)免於羰基化刺激之方法。
皮膚係身體抵禦外部環境刺激之第一道屏障。環境污染物(諸如微粒物質、紫外線、臭氧、及類似者)侵入皮膚之重要機制係通過氧化性損傷(oxidative damage)攻擊皮膚表層中之不飽和脂質,破壞皮膚最外層的保護層,並產生活性羰基物質,諸如丙二醛(malondialdehyde)、4-羥基壬烯醛(4- hydroxy nonenal)、丙烯醛(acrolein)等。當此等類型物質之含量超過身體的清除能力時,將發生羰基刺激(carbonyl stimuli),其誘發生物巨分子(諸如蛋白質)之羰基化修飾,導致結構改變及功能喪失。
在蛋白質羰基化期間,反應性醛或酮藉由氧化而被引入蛋白質中。已顯示蛋白質羰基(protein carbonyl)為蛋白質氧化之主要產物,且可經由以下方式形成:蛋白質之氧化性裂解、胺基酸殘基之直接氧化、或與衍生自脂質過氧化之醛的共價反應。
通常理解的是,蛋白質羰基化係指其中胺基酸殘基之側鏈中之胺基或亞胺基被氧自由基攻擊且最終轉化成醛基並釋放NH3+之過程,其中肽鍵斷裂,並在斷裂處生成羰基,且在蛋白質側鏈之胺基酸被羥基自由基攻擊並被氧化修飾之後,羰基之含量大幅地增加。
具體而言,蛋白質羰基化之所以發生是因為胺基酸側鏈之直接金屬催化之氧化(主要蛋白質羰基化)或因為將反應性醛添加至胺基酸側鏈(次要蛋白質羰基化)。照此,眾所周知,外源性起源之反應性醛(諸如丙烯醛)係衍生自香煙煙霧。
先前已有報導,主要蛋白質羰基化在活性含氧物(reactive oxygen species, ROS)信號傳導之機制中發揮作用。皮膚中之活性含氧物(ROS)會改變皮膚之細胞結構中之蛋白質。若活性含氧物(ROS)不能被皮膚抗氧化防禦系統完全控制,則皮膚中之蛋白質將會羰基化,導致皮膚損傷。
已充分記載,羰基蛋白質之產生係羰基化壓力(carbonylation stress)之標誌,該羰基化壓力例如由於外在因素,諸如藉由紫外線輻射或氧化性化學品之外部施用所誘發,或由於內在因素,諸如遭受衍生自脂質過氧化物之降解之反應性羰基的化學攻擊所致。
皮膚中之羰基化蛋白質主要存在於表皮及真皮中,且表皮中之羰基化蛋白質之含量係高於真皮中之含量。此係因為皮膚之表皮不斷地暴露於氧化性環境及有皮脂腺分泌之不飽和脂質環境中,為反應性醛化合物之持續生成創造有利的條件。
此外,羰基壓力導致皮膚損傷(諸如加速的皮膚老化)、或導致皮膚之各種病理反應。蛋白質羰基化損傷皮膚的保水能力,影響皮膚的透光率,並改變皮膚的光學性質等。具體而言,羰基化蛋白之存在與下列皮膚特性之改變相關:諸如力學性質(mechanical properties);保水能力,包括水份含量降低及表皮水分散失量(epidermal water loss)增加;皮膚暗沉;及皮膚透明度降低。同時,羰基化蛋白質之含量增加可導致發炎性皮膚疾病,諸如乾癬及皮膚炎。
因此,迫切需要能夠抑制或預防蛋白質羰基化之抗羰基化劑,以及包含抗羰基化劑之皮膚護理組成物及方法,以改善皮膚外觀或改善至少一種皮膚老化徵象(諸如保水能力降低、皮膚暗沉、皮膚泛黃、降低之皮膚透明度、彈性、對比度等),並減少發炎性皮膚疾病(諸如乾癬及皮膚炎)之發生。
本申請案涉及包含至少一種聚離胺酸之化妝品組成物。本申請案亦涉及用於減少或抑制角蛋白材料(尤其是皮膚)上之蛋白質羰基化之方法。
在包括請求項之整個說明書中,除非另有說明,否則用語「包含一(comprising a)」應當理解為與「包含至少一個(comprising at least one)」同義。此外,本說明書中所使用之表述「至少一個(at least one)」等同於表述「一或多個(one or more)」。
「局部施用(topical application」意指將組成物施加或塗抹在角蛋白材料之表面上,諸如皮膚之至少一個區域上。
如本文所使用,「抗羰基化(anti-carbonylation)」意指減少及/或抑制蛋白質羰基化,特別是保護組織(例如,角蛋白材料,尤其是(多種)角蛋白質纖維,諸如皮膚等)免於羰基化刺激。
如本文中所使用,「聚離胺酸(polylysine)」意指(多種)基於離胺酸之聚合物。
已出乎意料地發現,包含至少一種聚離胺酸(或由其所組成)之本發明抗羰基化組成物(或劑)可達成改善之抗羰基化功效。本申請案涉及作為化妝品組成物之本發明抗羰基化組成物(或劑),其包含至少一種聚離胺酸(或由其所組成)。本申請案亦涉及藉由施加包含本發明抗羰基化組成物(或劑)之組成物來減少及/或抑制角蛋白材料(尤其是(多種)角蛋白纖維,諸如皮膚)上之蛋白質羰基化之方法,該抗羰基化組成物包含至少一種聚離胺酸(或由其所組成)。
在一個實施例中,聚離胺酸較佳地係基於L-離胺酸之聚合物。
在另一實施例中,聚離胺酸可選自由下列所組成之群組:線性α-聚離胺酸、線性ε-聚離胺酸、超支化(hyperbranched)聚離胺酸、或樹枝狀聚離胺酸。
在一個實施例中,聚離胺酸較佳地係ε-聚離胺酸及/或樹枝狀聚離胺酸。
在其他實施例中,聚離胺酸具有多於200、甚至多於300、或多於400、較佳地多於500、或多於800之分子量。具體而言,聚離胺酸具有小於200000、甚至小於150000、或小於100000、較佳地小於50000、或小於20000之分子量。舉例而言,聚離胺酸具有在200與200000之間、甚至在400與100000之間、或在600與50000之間、或在800與20000之間、或在1000與15000之間、較佳地在1000與10000之間之分子量。當聚離胺酸係α-聚離胺酸時,α-聚離胺酸之較佳分子量係低於30000。
在其他實施例中,相對於化妝品組成物之總重量,聚離胺酸係以0.0001重量%至10重量%、較佳地0.001重量%至5重量%、較佳地0.001重量%至2重量%存在於該組成物中。
在其他實施例中,本發明組成物進一步包含功能劑,其可係諸如至少一種活性劑,諸如(多種)皮膚護理劑,該等皮膚護理劑係選自由下列所組成之群組:保濕劑(諸如蛋白質水解產物)、及多元醇(諸如甘油)、二元醇、聚乙二醇、及糖衍生物;天然萃取物;維生素,諸如維生素A(視黃醇)、維生素E(生育酚)、維生素C(抗壞血酸)、維生素B5(泛醇(panthenol))、維生素B3(菸鹼醯胺(niacinamide))、此等維生素(特別是酯類)之衍生物及其混合物;尿素;咖啡因;水楊酸及其衍生物;α-羥基酸,諸如乳酸及甘醇酸、及其衍生物;類視色素,諸如類胡蘿蔔素及維生素A衍生物;防曬劑;薄荷、蘆薈、或人參之精油及其混合物。
本申請案之另一主題係提供製備抗羰基化組成物之製程,該製程包含以下步驟:
- (1)可選地,提供配方基質,然後冷卻,例如冷卻至室溫,
- (2)將獲得之聚離胺酸分散在例如水中,
及
- (3)將1)配方基質、及2)含(多種)聚離胺酸之溶液在室溫下混合。
本申請案之另一主題係提供一種藉由施加本發明組成物來抵抗角蛋白材料(尤其是皮膚)之變性之非治療美容方法(non-therapy cosmetic method)。
本申請案之另一主題係提供一種藉由施加本發明抗羰基化組成物來護理角蛋白材料(尤其是皮膚)之非治療美容方法。
本申請案之另一主題係關於本發明組成物之用途、或製備護理角蛋白材料(尤其是皮膚)之產品之用途。
本申請案之另一主題係提供包含本發明組成物之化妝品產品。
本申請案之其他特性及優點將在閱讀本說明書及以下實例後更加清楚地顯現。
在本申請案中,除非另有具體說明,否則含量、份數、及百分比之表示均以重量計。
聚離胺酸
聚離胺酸係指數種類型的基於離胺酸之均聚物,其等從立體化學及連接位置方面而言可彼此不同。離胺酸(人類必需胺基酸)係聚離胺酸之主要建構嵌段(building block),且有兩種掌性形式:L-離胺酸及D-離胺酸。特定掌性離胺酸單體之聚合將分別導致L-聚離胺酸及D-聚離胺酸。前體胺基酸離胺酸含有兩個胺基,一個位在α-碳處而一個位在ε-碳處。兩者中任何一者均可係聚合位置,導致α-聚離胺酸或ε-聚離胺酸。聚離胺酸可根據該聚合物鏈之形狀結構(topology)進一步分類成線性、超支化、及樹枝狀聚離胺酸。聚離胺酸之分子量可在100至1000000之範圍。
在本申請案中,聚離胺酸係指基於離胺酸之聚合物,諸如線性ε-聚離胺酸(ε-PL)、線性α-聚離胺酸(α-PL),、超支化聚離胺酸、及樹枝狀聚離胺酸。
一般而言,聚離胺酸係以以下濃度存在於局部組成物中:0.0001重量%至10重量%、較佳地0.001重量%至5重量%、較佳地0.001重量%至2重量%,其係相對於組成物之總重量計。
聚離胺酸結構
申請人驚訝地發現,聚離胺酸在抗羰基化功效方面優於單體離胺酸,在不希望受理論束縛的情況下,可選地其濃度例如在0.005%至0.05%之範圍,此可能有助于該聚合物鏈之「多價效應(multivalent effect)」。
令人驚訝地,在不希望受理論束縛的情況下,聚離胺酸較佳地係選自ε-聚離胺酸及/或樹枝狀聚離胺酸。
活性劑
根據本申請案之實施例,本申請案之產品可包含至少一種功能劑,諸如至少一種活性劑,該至少一種活性劑例如選自由下列所組成之群組:去皮屑劑(desquamating agent)或保濕劑;脫色劑或抗脫色劑;抗醣化劑;抗NO劑;用於刺激真皮或表皮巨分子之合成及/或用於預防其降解之劑;用於刺激纖維母細胞或角質細胞增殖及/或角質細胞分化之劑;肌肉鬆弛劑或皮膚鬆弛劑(dermo-decontracting agent);自由基清除劑或抗污染劑;緊縮劑(tensioning agent);作用於微血管循環(capillary circulation)之劑;當然,還有以下特別提出之活性劑、及其混合物。
在可用於本申請案中之所有活性劑中,特别值得一提的是:α-或β-羥基酸,諸如乳酸、甘醇酸、檸檬酸、5-辛醯基水楊酸、α-羥基癸酸、α-羥基月桂酸、酒石酸、葡萄糖醛酸、半乳糖醛酸、丙烯酸、α-羥基丁酸、α-羥基異丁酸、蘋果酸、扁桃酸、磷酸、丙酮酸、乳糖醛酸、及水楊酸。
亦可使用抗痘劑(諸如水楊酸或過氧化苯甲醯、羥甲辛吡酮(octopirox)、右旋及左旋含硫之胺基酸、其鹽、及其N-乙醯基衍生物(諸如N-乙醯基半胱胺酸))、或試圖預防皮膚老化及/或改善其狀態之劑(例如上述之α-及β-羥基酸)、類視色素(諸如視黃酸、視黃醇、及其酯,諸如例如丙酸視黃酯、及乙酸視黃酯、或棕櫚酸視黃酯)、菸鹼醯胺、尿囊素(allantoin)、蘆薈之萃取物、壬二酸(azelaic acid)、甜沒藥醇(bisabolol)、植物酸(phytic acid)、膠原蛋白、或刺激膠原蛋白之形成之劑、維生素,諸如維生素C或其衍生物(諸如抗壞血酸糖苷(ascorbyl glucoside))、維生素E或其衍生物、維生素A或其衍生物、維生素F或其衍生物、如上述之右旋及左旋含硫之胺基酸及其衍生物、彈性蛋白、N-乙醯基D-葡萄糖胺、木犀草素(luteolin)、或抗氧化劑(諸如綠茶或其活性部分)、甘油、鋰皂石(laponite)、咖啡因、芳族香精油(essential aromatic oil)、著色劑、自由基清除劑、保溼劑、脫色劑、用於改善膚色之劑(諸如二羥基丙酮或酪胺酸酯類型之人工曬黑劑(artificial-tanning agent))、皮脂調節劑(liporegulator)、軟化劑、抗皺劑、角質層分離劑(keratolytic agent)、清新劑、除臭劑、麻醉劑、營養劑、及其混合物。亦可使用漂白劑,諸如麴酸(kojic acid)、抗壞血酸磷酸酯、抗壞血酸糖苷、抗壞血酸、及其混合物。
在面膜之情況下,亦可使用用於改善皮膚狀況之活性劑,諸如保濕劑或用於改善天然脂質屏障之劑,諸如神經醯胺、膽固醇硫酸酯、及/或脂肪酸、及其混合物。亦可使用對皮膚具有活性的酶,諸如蛋白酶、脂肪酶、腦苷脂酶、及/或麥拉寧酶(melanases)、及其混合物。
作為可適用於實施本申請案的活性劑之其他實例還有下列之劑:藥物、肽、蛋白質、可偵測之標記、造影試劑(contrast reagent)、止痛劑、麻醉劑、抗菌劑、抗酵母劑、抗真菌劑、抗病毒劑、抗皮膚炎劑、止癢劑、止吐劑(anti-emetics)、血管保護劑、防動暈劑(agent against motion sickness)、抗刺激劑、消炎劑、免疫調節劑、抗角化過度劑(anti-hyperkeratolytic agent)、用於治療乾性皮膚之劑、止汗劑、抗乾癬劑、抗頭皮屑劑(antidandruff agent)、抗老化劑、抗氣喘劑及支氣管擴張劑(bronchodilator)、防曬劑、抗組織胺劑、療治劑(healing agent)、皮質類固醇劑、曬黑劑、及其混合物。
可隨組成物之預期目的來調整組成物中至少一種活性劑之含量。
佐劑
在已知方式中,本申請案之組成物亦可含有在化妝品及/或皮膚科中常見的佐劑,諸如防腐劑、抗氧化劑、pH調整劑(酸性或鹼性)、芳香劑、填料、殺菌劑、氣味吸收劑、著色劑(顏料及染料)、乳化劑、還有脂質囊泡(lipid vesicle)。
當然,所屬技術領域中具有通常知識者將小心選擇此種或此等可選的(多種)額外化合物、及/或其量,使得所設想之添加不會或實質上不會不利地影響根據本申請案之組成物之益處。
儘管闡述本申請案之廣泛範疇的數值範圍及參數為近似值,但在具體實例中盡可能的精確報告闡述之數值。然而,任何數值均固有地含有由在其各自測量中存在之標準偏差所必然產生的某些誤差。以下實例意欲說明本申請案,而不因此限制本申請案之範疇。
實例
下述之組成物/配方中之成分量/濃度係以重量份表示。
I.本發明組成物之評估
1.體外抗羰基化功效測試
此檢定提供一種測定抗羰基化劑/組成物如何影響蛋白質羰基化之程度的體外方法。用去離子水將待測試之抗羰基化劑/組成物製成1%溶液,將牛血清白蛋白(Bovine Serum Albumin, BSA)製成10 mg/mL溶液,並將丙烯醛製成10 mM溶液。然後,在1.5 mL離心管中,根據表1中之含量,將BSA (10 mg/mL)、抗羰基化劑/組成物(1%)、丙烯醛(10 mM)、及磷酸鹽緩衝溶液(Phosphate buffer solution, PBS)添加至離心管中。將僅含有BSA及PBS之樣本充當基線,並將含有BSA、丙烯醛、及PBS之樣本充當空白組。在各離心管中之最終液體體積係1.0 mL。各群組均含有三個重複樣本,且所有樣本均在37℃下放置隔夜。
1. ε-PL係來自Chisso corporation
2. 樹枝狀PL係來自Lucas Meyer之DENDIRCLEAR。
[表1] | |||||
抗羰基化劑及工作濃度 | 10 mg/mL BSA (µL) | 1%抗羰基化劑(µL) | 10 mM丙烯醛 (µL) | PBS (µL) | |
對照組 | 基線(沒有活性添加) | 100 | 0 | 0 | 900 |
空白組(沒有活性添加) | 100 | 0 | 100 | 800 | |
基準點 | L-離胺酸0.005% | 100 | 5 | 100 | 795 |
L-離胺酸0.05% | 100 | 50 | 100 | 750 | |
線性α- PL | α- PL (1K-5K) 0.005% | 100 | 5 | 100 | 795 |
α- PL (1K-5K) 0.05% | 100 | 50 | 100 | 750 | |
α- PL (30K-70K) 0.005% | 100 | 5 | 100 | 795 | |
α- PL (30K-70K) 0.05% | 100 | 50 | 100 | 750 | |
α- PL (70K-150K) 0.005% | 100 | 5 | 100 | 795 | |
α- PL (70K-150K) 0.05% | 100 | 50 | 100 | 750 | |
線性ε-PL | ε-PL 10.005% | 100 | 5 | 100 | 795 |
ε-PL 0.05% | 100 | 50 | 100 | 750 | |
樹枝狀PL | 樹枝狀PL 20.005% | 100 | 5 | 100 | 795 |
樹枝狀PL 0.05% | 100 | 50 | 100 | 750 |
藉由使用南京建成生物工程研究所(Nanjing Jiancheng Bioengineering Institute)之蛋白質羰基檢定套組來偵測上文樣品中之蛋白質羰基含量。偵測方法如下:將0.1 mL樣本加入檢定管中,然後添加0.4 mL的套組中之試劑3,渦旋混合1分鐘,然後在37℃下避光反應30分鐘。添加0.5 mL的套組中之試劑5、渦旋並混合1分鐘,在4℃下以12,000 r/min離心10分鐘,丟棄上清液,並留下沉澱物。添加1.0 mL的無水乙醇及乙酸乙酯(1:1)混合溶液,渦旋混合1分鐘,在4℃下以12,000 r/min離心10分鐘,丟棄上清液,留下沉澱物,並重複上述步驟四次。添加1.25 mL的套組中之試劑VI,混合均勻,將其放置於37℃下15分鐘,渦旋混合使所有沉澱溶解,並以12,000 r/min離心15分鐘。將上清液加入具有0.5 cm之光直徑的石英比色管中,用試劑六調整歸零,並測量各管在370 nm(紫外線)下之吸光值。根據公式,吾等可得到蛋白質羰基含量。
蛋白質羰基含量(nmol/mgprot) =
使用Thermos's Micro BCA
™蛋白質檢定套組來測定樣本之蛋白質含量。首先,製備經稀釋之白蛋白(BSA)標準品(工作範圍= 20至750 µg/mL)。將BCA試劑A與試劑B(試劑A:試劑B = 50:1)混合以製備工作溶液。將不同稀釋濃度之蛋白質標準品及蛋白質樣本各自取25 µL添加至微孔板(microplate)中。將200 µL的工作溶液添加至各孔中並藉由在振盪器上振盪30秒來混合均勻。將微孔板密封並在37℃下培育30分鐘。將微孔板冷卻至室溫並測量樣品在562 nm之波長下之吸光度。經校正之吸光值係將來自各標準品及樣本之讀數減去空白樣本之吸光值。對照用已知量的BSA所製備之標準曲線來讀取蛋白質濃度。參照標準曲線,在標準曲線之線性範圍內根據各蛋白質樣品之經校正之吸光值讀取各樣本之蛋白質濃度。基於樣本體積及稀釋度來計算原始樣本中蛋白質之量。
2.聚離胺酸之抗羰基化功效
各抗羰基化劑/組成物之抗羰基化能力可藉由將樣品之羰基化程度除以BSA蛋白質含量來獲得。結果顯示於下表2及表3中。
[表2] | |||||
抗羰基化劑 | 蛋白質羰基化水平之百分比(平均值) | 羰基化之抑制%(平均值) | SD | P值(對比基準點) | |
對照組 | 空白組(沒有活性添加) | 100% | 0% | NA | NA |
基準點 | L-離胺酸0.005% | 79% | 21% | 5% | NA |
線性α- PL | α- PL (1K-5K) 0.005% | 50% | 50% | 2% | 0.0021 |
α- PL (30K-70K) 0.005% | 89% | 11% | 14% | 0.4163 | |
α- PL (70K-150K) 0.005% | 84% | 16% | 9% | 0.5880 | |
線性ε-PL | ε-PL 0.005% | 33% | 67% | 3% | 0.0010 |
樹枝狀PL | 樹枝狀PL 0.005% | 43% | 57% | 3% | 0.0016 |
[表3] | |||||
抗羰基化劑 | 蛋白質羰基化水平之百分比(平均值) | 羰基化之抑制%(平均值) | SD | P值(對比基準點) | |
對照組 | 空白組(沒有活性添加) | 100% | 0% | NA | NA |
基準點 | L-離胺酸0.05% | 60% | 40% | 14% | NA |
線性α- PL | α- PL (1K-5K) 0.05% | 49% | 51% | 11% | 0.3474 |
α- PL (30K-70K) 0.05% | 78% | 22% | 4% | 0.0928 | |
α- PL (70K-150K) 0.05% | 60% | 40% | 4% | 0.4537 | |
線性ε-PL | ε-PL 0.05% | 5% | 95% | 3% | 0.0025 |
樹枝狀PL | 樹枝狀PL 0.05% | 19% | 81% | 11% | 0.0160 |
如上所示,聚離胺酸減少及/或抑制蛋白質羰基化。
II.配方實例
藉由充分混合如下此等成分來製備含有聚離胺酸之本發明之組成物。
III.抗羰基化組成物之感官品評
組成物 | 1 | 2 | 3 | 4 |
油醇聚醚-3-磷酸酯(oleth-3 phosphate) | 0.45 | 0.45 | 0.45 | 0.45 |
油醇聚醚-3 | 0.35 | 0.35 | 0.35 | 0.35 |
油醇聚醚-5 | 0.24 | 0.24 | 0.24 | 0.24 |
丁二醇 | 1.3 | 1.3 | 1.3 | 1.3 |
鯊烷(squalane) | 0.5 | 0.5 | 0.5 | 0.5 |
BHT | 0.1 | 0.1 | 0.1 | 0.1 |
甲氧基肉桂酸乙基己酯 | 0.1 | 0.1 | 0.1 | 0.1 |
膽固醇聚醚-24 (choleth-24)/鯨蠟醇聚醚-24 (ceteth-24) | 0.1 | 0.1 | 0.1 | 0.1 |
三乙醇胺 | 0.61 | 0.61 | 0.61 | 0.61 |
棕櫚酸視黃酯/玉米油/BHT/BHA | 0.1 | 0.1 | 0.1 | 0.1 |
甜沒藥醇 | 0.1 | 0.1 | 0.1 | 0.1 |
對羥苯甲酸甲酯 | 0.46 | 0.46 | 0.46 | 0.46 |
PEG-75 | 4 | 4 | 4 | 4 |
雙-PEG-18甲基醚二甲基矽烷 | 2 | 2 | 2 | 2 |
甘油聚醚-26 (glycereth-26) | 1 | 1 | 1 | 1 |
甲基葡糖醇聚醚-20 (methyl gluceth-20) | 4 | 4 | 4 | 4 |
EDTA三鈉 | 0.1 | 0.1 | 0.1 | 0.1 |
泛雙硫醇(pantethine) | 0.14 | 0.14 | 0.14 | 0.14 |
三仙膠 | 0.075 | 0.075 | 0.075 | 0.075 |
苯氧乙醇 | 0.72 | 0.72 | 0.72 | 0.72 |
核糖核酸鈉 | 0.01 | 0.01 | 0.01 | 0.01 |
玻糖醛酸鈉 | 0.01 | 0.01 | 0.01 | 0.01 |
ε-聚離胺酸25%溶液 (可購自Chisso,Mw=3200-4500) | 0.4 | 0.2 | ||
DendriClear(可購自Lucas Meye,樹枝狀聚離胺酸,Mw=6171) | 0.4 | 0.2 | ||
水 | 至100 | 至100 | 至100 | 至100 |
組成物1至4之感官性質係在將其施加至皮膚之後進行品評,並總結於下表中:
組成物 | 感官品評 |
1 | 塗抹性良好,殘留柔軟度(residual softness)良好,中等膠黏性 |
2 | 塗抹性良好,殘留柔軟度良好,低膠黏性 |
3 | 塗抹性良好,殘留柔軟度良好,低膠黏性 |
4 | 塗抹性良好,殘留柔軟度良好,低膠黏性 |
組成物1至4之化妝品性質良好,尤其從塗抹性、柔軟度、及無膠黏性方面而言。
雖然已就較佳實施例來描述本發明,但並非意欲將本發明之範疇限於所闡述之特定形式,相反地,其意欲涵蓋可包括在本發明之精神及範疇內的替代、修改、及等效物,該精神及範疇係由隨附申請專利範圍所界定。
無
無
Claims (14)
- 一種抗羰基化組成物,其包含至少一種聚離胺酸。
- 如請求項1之抗羰基化組成物,其中該聚離胺酸係選自由至少一種基於離胺酸之聚合物所組成之群組。
- 如前述請求項中任一項之抗羰基化組成物,其中該至少一種聚離胺酸係基於L-離胺酸之聚合物。
- 如前述請求項中任一項之抗羰基化組成物,其中該至少一種聚離胺酸係選自由下列所組成之群組:α-聚離胺酸、ε-聚離胺酸、超支化聚離胺酸、及樹枝狀聚離胺酸,較佳地係選自由ε-聚離胺酸及/或樹枝狀聚離胺酸所組成之群組。
- 如前述請求項中任一項之抗羰基化組成物,其中該至少一種聚離胺酸具有多於200、甚至多於300、或多於400、較佳地多於500、或多於800之分子量;具體而言,該聚離胺酸具有小於200000、甚至小於150000、或小於100000、較佳地小於50000、或小於20000之分子量,諸如該聚離胺酸具有在200與200000之間、甚至在400與100000之間、或在600與50000之間、或在800與20000之間、或在1000與15000之間、較佳地在1000與10000之間之分子量。
- 如前述請求項中任一項之抗羰基化組成物,其中,當該聚離胺酸係α-聚離胺酸時,α-聚離胺酸之分子量低於30000。
- 如前述請求項中任一項之抗羰基化組成物,其中相對於該組成物之總重量,該至少一種聚離胺酸係以0.0001重量%至10重量%、較佳地0.001重量%至5重量%、較佳地0.001重量%至2重量%存在於該組成物中。
- 如前述請求項中任一項之抗羰基化組成物,其中該組成物進一步包含至少一種功能劑,諸如至少一種活性劑,諸如(多種)皮膚護理劑,較佳地,該等皮膚護理劑係選自由下列所組成之群組:由保濕劑(諸如蛋白質水解產物)、及多元醇(例如甘油)、二元醇(例如聚乙二醇)、及糖衍生物所組成之群組;天然萃取物;維生素,諸如維生素A(視黃醇)、維生素E(生育酚)、維生素C(抗壞血酸)、維生素B5(泛醇)、維生素B3(菸鹼醯胺)、此等維生素(特別是酯類)之衍生物及其混合物;尿素;咖啡因;水楊酸及其衍生物;α-羥基酸,諸如乳酸及甘醇酸、及其衍生物;類視色素,諸如類胡蘿蔔素及維生素A衍生物;防曬劑;薄荷、蘆薈、或人參之精油及其混合物。
- 一種化妝品產品,其包含如前述請求項1至8中任一項之抗羰基化組成物。
- 一種製備如前述請求項1至8中任一項之抗羰基化組成物或如請求項9之化妝品產品之製程,其包含以下步驟: - (1)可選地,提供配方基質,然後冷卻,例如冷卻至室溫, - (2)將(多種)聚離胺酸分散在例如水中, 及 - (3)將1)配方基質及2)(多種)聚離胺酸溶液在室溫下混合。
- 一種用於藉由施加如前述請求項1至8中任一項之抗羰基化組成物或如請求項9之化妝品產品來減少及/或抑制角蛋白材料上之蛋白質羰基化之非治療性美容方法,尤其是皮膚上之蛋白質羰基化。
- 一種用於藉由施加如前述請求項1至8中任一項之抗羰基化組成物或如請求項9之化妝品產品來護理角蛋白材料之非治療性美容方法,尤其是護理皮膚。
- 一種如前述請求項1至8中任一項之組成物或如請求項9之化妝品產品用於製備護理角蛋白材料之產品之用途,尤其是護理皮膚之產品。
- 一種如前述請求項1至8中任一項之組成物或如請求項9之化妝品產品用於製備減少或阻止角蛋白材料上之蛋白質羰基化之產品之用途,尤其是皮膚上之蛋白質羰基化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WOPCT/CN2022/110203 | 2022-08-04 | ||
PCT/CN2022/110203 WO2024026766A1 (en) | 2022-08-04 | 2022-08-04 | Anti-carbonylation composition and method of protecting keratin materials from carbonylation stimuli by using compositions including polylysines |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202406532A true TW202406532A (zh) | 2024-02-16 |
Family
ID=89848187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112128308A TW202406532A (zh) | 2022-08-04 | 2023-07-28 | 抗羰基化組成物及藉由使用包括聚離胺酸之組成物來保護角蛋白材料免於羰基化刺激之方法 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202406532A (zh) |
WO (1) | WO2024026766A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004026743A (ja) * | 2002-06-27 | 2004-01-29 | Chisso Corp | ポリリジン製剤およびこれを含有する化粧料組成物 |
JP4947034B2 (ja) * | 2008-10-30 | 2012-06-06 | Jnc株式会社 | ポリリジン製剤およびこれを含有する化粧料組成物 |
DE102011077040A1 (de) * | 2011-06-07 | 2012-12-13 | Beiersdorf Ag | Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und einem oder mehrerenethoxylierten und/oder propoxylierten Alkanolen |
JP6596098B2 (ja) * | 2015-04-03 | 2019-10-23 | イーエルシー マネージメント エルエルシー | 毛髪処理組成物 |
JP2018090507A (ja) * | 2016-11-30 | 2018-06-14 | 上野製薬株式会社 | カルボニル化抑制剤 |
KR102022184B1 (ko) * | 2018-03-06 | 2019-09-18 | (주)신승하이켐 | 폴리리신을 포함하는 화장료 조성물 |
-
2022
- 2022-08-04 WO PCT/CN2022/110203 patent/WO2024026766A1/en unknown
-
2023
- 2023-07-28 TW TW112128308A patent/TW202406532A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024026766A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3532244B2 (ja) | ムコ多糖類断片化抑制剤、活性酸素消去剤および化粧料 | |
CN1200687C (zh) | 包含n-乙烯基咪唑聚合物或共聚物和氧化敏感亲水有效成分的组合物的化妆用途 | |
JP3638832B2 (ja) | 少なくとも1のクワの抽出物、少なくとも1のタツナミソウの抽出物および少なくとも1のサリチル酸誘導体を含む化粧用及び/又は皮膚科学用組成物 | |
EP3532019B1 (en) | Skin enhancing compositions and methods | |
CA2749750A1 (en) | Skin care compositions and methods of use thereof | |
JPH0930921A (ja) | 皮膚のしみおよび/または老化を処置する組成物並びにその使用 | |
FR2885804A1 (fr) | Compositions de soins pour la peau, produits les contenant et procedes les utilisant | |
KR100816314B1 (ko) | 피부 질감 개선제 | |
JPH09291011A (ja) | 外用に適する組成物 | |
IES20060449A2 (en) | Cosmetic compositions containing lingonberry (vaccinium vitis idea) extracts | |
KR20050103903A (ko) | 노화되거나 환경에 손상된 피부를 치료하기 위한 국소적조성물 및 치료 방법 | |
JPH07309739A (ja) | ムコ多糖類断片化抑制剤および化粧料 | |
KR100440357B1 (ko) | 세포증식 및 피부 보습에 의한 탄력 증강 효능을 갖는레반 추출물을 함유한 화장료 조성물 | |
TW202406532A (zh) | 抗羰基化組成物及藉由使用包括聚離胺酸之組成物來保護角蛋白材料免於羰基化刺激之方法 | |
JP2011195539A (ja) | エラスターゼ活性阻害剤 | |
JP4594580B2 (ja) | 蛋白質のカルボニル化抑制剤、皮膚外用剤及び方法 | |
JP2002370962A (ja) | 美白用化粧料および皮膚老化防止・改善用化粧料 | |
JP2011207778A (ja) | 皮膚外用剤又は化粧料 | |
WO2020172455A1 (en) | Synergistic antioxidant compositions | |
KR20090028275A (ko) | 에센셜 오일 조합을 주성분으로 하는피부 노화방지와주름개선 효과를 갖는 화장료 및 그 제조방법 | |
KR20210039636A (ko) | 피부 보습용 화장료 조성물 및 이의 제조방법 | |
EP3366273A1 (en) | Moisturizer and cosmetic containing same | |
WO1999009945A1 (fr) | Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
CN117426999B (zh) | 一种可循环抗氧剂高效递送纳米复合物及其制备方法 | |
JP2004175688A (ja) | 美白剤及び化粧料 |